"10.1371_journal.pone.0045182","none","2012-09-18T00:00:00Z","Fabrice D Heitz; Michael Erb; Corinne Anklin; Dimitri Robay; Vincent Pernet; Nuri Gueven","Santhera Pharmaceuticals, Liestal, Switzerland; Brain Research Institute, Medical Faculty of the University of Zürich, Zürich, Switzerland; School of Pharmacy, University of Tasmania, Hobart, Australia","Conceived and designed the experiments: FDH NG. Performed the experiments: FDH ME CA DR. Analyzed the data: FDH ME NG. Contributed reagents/materials/analysis tools: VP. Wrote the paper: FDH NG.","The authors have read the journal’s policy and have the following conflicts: During the preparation of this manuscript, all authors except VP were paid employees of Santhera Pharmaceuticals (Switzerland). Santhera is marketing Catena® (idebenone) for the treatment of Friedreich’s Ataxia in Canada and develops Catena for several other mitochondrial and neuromuscular indications. NG is academic editor of PLOS ONE. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.",NA,NA,NA,"2012","09","Fabrice D Heitz","FDH",6,TRUE,2,4,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
